<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461224</url>
  </required_header>
  <id_info>
    <org_study_id>MARA-1</org_study_id>
    <nct_id>NCT03461224</nct_id>
  </id_info>
  <brief_title>Modulated Accelerated RAdiotherapy in Early Breast Cancer</brief_title>
  <official_title>Postoperative Modulated Accelerated RAdiotherapy (MARA-1) for Early Stage Breast Cancer: a Retrospective Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial was a retrospective study on postoperative accelerated hypofractionated IMRT&#xD;
      (MARA-1) in patients with early stage breast carcinoma, to compare late toxicity after this&#xD;
      treatment and standard fractionated RT delivered with 3D-CRT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to evaluate the clinical results in terms of late skin and&#xD;
      subcutaneous toxicity of accelerated hypofractionated forward-planned IMRT in patients with&#xD;
      early stage BC. Results were compared with a historical control group (CG) of patients&#xD;
      treated with 3D-conformal postoperative RT delivered with conventional fractionation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2001</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-related late adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>late toxicity (cutaneous and subcutaneous) is evaluated using RTOG/EORTC criteria in both groups of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related acute adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>acute toxicity (cutaneous and subcutaneous) is evaluated using RTOG/EORTC criteria in both groups of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local control</measure>
    <time_frame>5 years</time_frame>
    <description>absence of locoregional relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>defined as the time from diagnosis to death</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">447</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Radiation Toxicity</condition>
  <arm_group>
    <arm_group_label>MARA-1: accelerated hypofractionated RT</arm_group_label>
    <description>A forward planned IMRT technique was used and the prescribed dose to the breast was 40 Gy in 16 fx with a concomitant boost of 4 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CG: conventional fractionated RT</arm_group_label>
    <description>In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) delivered with 3D-RT, followed by a sequential boost on the tumour bed of 10 Gy in 4 fx delivered with electrons</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>accelerated hypofractionated RT</intervention_name>
    <arm_group_label>MARA-1: accelerated hypofractionated RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>conventional fractionated RT</intervention_name>
    <arm_group_label>CG: conventional fractionated RT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        From 2003, all women fullfilling the inclusion criteria were treated with MARA-1 scheme&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed histologic evidence of pTis-pT3 breast cancer&#xD;
&#xD;
          -  breast conservative surgery&#xD;
&#xD;
          -  post menopausal status&#xD;
&#xD;
          -  clear surgical margin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pT4&#xD;
&#xD;
          -  positive or close resection margins&#xD;
&#xD;
          -  3 or more metastatic axillary nodes&#xD;
&#xD;
          -  nodal irradiation&#xD;
&#xD;
          -  M1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessio G. Morganti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology Center, Department of Experimental, Diagnostic and Speciality Medicine-DIMES, Unversity of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>Alessio Giuseppe Morganti</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>cutaneous toxicity</keyword>
  <keyword>subcutaneous toxicity</keyword>
  <keyword>IMRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

